Chest. 1997 Oct;112(4):1079-90.

Nonpharmacologic treatment of atrial fibrillation: current and evolving strategies.

Iskos D, Fahy GJ, Lurie KG, Sakaguchi S, Adkisson WO, Benditt DG.

Source

Cardiac Arrhythmia Center, Department of Medicine, University of Minnesota Medical School, Minneapolis, USA.

Abstract

Atrial fibrillation is the most common cardiac arrhythmia requiring treatment. Limitations of medical treatment have prompted development of nonpharmacologic therapies for this arrhythmia. These are aimed at ventricular rate control during atrial fibrillation, termination of the arrhythmia, and/or prevention of recurrences. Ventricular rate control can be achieved with transcatheter ablation or modification of the atrioventricular node. The MAZE operation is effective in preventing arrhythmia recurrence, but because it requires cardiac surgery, its appeal is limited. Development of the technique for direct transcatheter ablation of atrial fibrillation is eagerly anticipated and may represent the standard curative treatment of the future. In appropriately selected patients, implantable device therapy may play an important role in the treatment of paroxysmal atrial fibrillation.

PMID:: 9377921; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Anti-Arrhythmia Agents

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Atrial Fibrillation - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Nonpharmacologic strategies for treating atrial fibrillation. [Am J Cardiol. 1996]
Review Nonpharmacologic strategies for treating atrial fibrillation.
Lüderitz B, Pfeiffer D, Tebbenjohanns J, Jung W. Am J Cardiol. 1996 Jan 25; 77(3):45A-52A.
Review Atrial fibrillation: the nonpharmacologic strategy. [Mt Sinai J Med. 2002]
Review Atrial fibrillation: the nonpharmacologic strategy.
Lee J. Mt Sinai J Med. 2002 Sep; 69(4):232-41.
Review Atrioventricular node modification and ablation for ventricular rate control in atrial fibrillation. [Heart Rhythm. 2007]
Review Atrioventricular node modification and ablation for ventricular rate control in atrial fibrillation.
Feld GK. Heart Rhythm. 2007 Mar; 4(3 Suppl):S80-3. Epub 2006 Dec 15.
[Resistant atrial fibrillation: how far does one go in its treatment?]. [Rev Med Brux. 1999]
[Resistant atrial fibrillation: how far does one go in its treatment?].
Verbeet T. Rev Med Brux. 1999 Sep; 20(4):A237-44.
Prospective, randomized study of atrioventricular ablation and mode-switching, dual chamber pacemaker implantation versus medical therapy in drug-resistant paroxysmal atrial fibrillation. The PAF study. Paroxysmal Atrial Fibrillation. [Europace. 1999]
Prospective, randomized study of atrioventricular ablation and mode-switching, dual chamber pacemaker implantation versus medical therapy in drug-resistant paroxysmal atrial fibrillation. The PAF study. Paroxysmal Atrial Fibrillation.
Brignole M, Gianfranchi L, Menozzi C, Alboni P, Musso G, Bongiorni MG, Gasparini M, Raviele A, Lolli G, Paparella N, et al. Europace. 1999 Jan; 1(1):15-9.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Nonpharmacologic treatment of atrial fibrillation: current and evolving strategi...
Nonpharmacologic treatment of atrial fibrillation: current and evolving strategies.
Chest. 1997 Oct ;112(4):1079-90.

PubMed
Transmuting alpha helices and beta sheets.
Transmuting alpha helices and beta sheets.
Fold Des. 1997 ;2(5):R71-9.

PubMed
Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atop...
Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis.
Clin Ther. 1997 Jul-Aug ;19(4):710-9.

PubMed
Clindamycin enhances a nondepolarizing neuromuscular blockade.
Clindamycin enhances a nondepolarizing neuromuscular blockade.
Anesthesiology. 1976 Jul ;45(1):84-7.

PubMed
Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic p...
Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Cancer Res. 1997 Oct 15 ;57(20):4465-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: